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Abstract
Introduction: Nodular thyroid disease is one of the most frequently diagnosed pathologies of the adult population in iodine-deficient 
regions. Approximately 30% of thyroid aspirates are classified as nondiagnostic/unsatisfactory or indeterminate. However, patients with 
indeterminate cytology still undergo surgery. The object of this study was to determine the diagnostic value of re-examining the BRAF 
V600E mutation in papillary thyroid carcinoma patients. 
Material and methods: All patients underwent ultrasound guided fine-needle aspiration of a thyroid nodule. They were assigned to one 
of the four groups (indeterminate or positive for malignant cells) of the Bethesda System for Reporting Thyroid Cytopathology. Genetic 
investigation of the BRAF V600E mutation was performed for all of the fine-needle aspiration cytology specimens. All of the patients un-
derwent surgery. Subsequently, histological investigation of the removed tissues was performed. Additional analysis of the BRAF V600E 
mutation from the histology specimen was then performed for the initially BRAF-negative cases. 
Results: Two hundred and fourteen patients were involved in the study. One hundred and six (49.53%) patients were diagnosed 
with thyroid cancer. Of these 106 patients, 95 (89.62%) patients were diagnosed with papillary thyroid cancer. The BRAF V600E 
mutation was positive in 62 (65.26%) and negative in 33 (34.74%) histologically confirmed papillary thyroid cancer cases. After 
the genetic investigation, a total of 74 (77.89%) papillary thyroid cancer cases were positive for the BRAF V600E mutation and 
21 (22.11%) were negative. 
Conclusions: Repeated examination of the BRAF V600E mutation status in the fine-needle aspiration may potentially increase the sensi-
tivity of papillary thyroid cancer diagnostics. (Endokrynol Pol 2016; 67 (1):  35–40)
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Streszczenie
Wstęp: Choroba guzkowa tarczycy to jedna z najczęściej wykrywanych patologii w populacji osób dorosłych w regionach z deficytem 
jodu. Około 30% aspiratów tarczycy jest klasyfikowanych jako nie do zdiagnozowania/niesatysfakcjonujące lub nieokreślone. Jednakże, 
pacjenci z nieokreślonym wynikiem cytologii nadal poddawani są operacjom. Celem niniejszego badania było ustalenie wartości diagno-
stycznej powtórnego badania mutacji genu BRAF V600E wśród pacjentów z rakiem brodawkowatym tarczycy.
Materiał i metody: Wszystkich pacjentów poddano biopsji aspiracyjnej cienkoigłowej guzka tarczycy pod kontrolą USG. Przydzielono 
ich do jednej z czterech grup (nieokreślona lub dodatnia dla komórek złośliwych) klasyfikacji Bethesda do klasy obrazów cytologicznych. 
Badanie genetyczne mutacji genu BRAF V600E przeprowadzono dla wszystkich próbek uzyskanych z aspiracyjnej cytologii cienkoigłowej. 
Wszystkich pacjentów zoperowano. Jednocześnie przeprowadzono badanie histologiczne usuniętych tkanek. Dodatkowa analiza mutacji 
BRAF V600E z próbki histologicznej została przeprowadzona dla przypadków początkowo BRAF ujemnych.
Wyniki: Dwustu czternastu pacjentów poddano badaniu. U 106 pacjentów (49,53%) zdiagnozowano raka tarczycy. Z tychże pacjentów, 
u 95 (89,62%) zdiagnozowano raka brodawkowatego tarczycy. U 62 pacjentów (65,26%) mutacja BRAF V600E była dodatnia, u 33 (34,74%) 
histologicznie potwierdzonych przypadków raka brodawkowatego tarczycy była ona ujemna. Po badaniu genetycznym stwierdzono 
74 (77,89%) przypadki raka brodawkowatego tarczycy dodatnich dla mutacji BRAF V600E i 21 (22,11%) ujemnych. 
Wnioski: Powtórne badanie mutacji genu BRAF V600E za pomocą aspiracji cienkoigłowej może potencjalnie przyczynić się do zwiększenia 
czujności w wykrywaniu raka brodawkowatego tarczycy. (Endokrynol Pol 2016; 67 (1):  35–40)
Słowa kluczowe: mutacja BRAF; rak tarczycy; aspiracja cienkoigłowa
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Reporting Thyroid Cytopathology (BSRTC) into the 
following groups: Nondiagnostic or Unsatisfactory 
(ND/UNS) cytology, benign, atypia of undetermined 
significance/follicular lesion of undetermined signifi-
cance (AUS/FLUS), follicular or oncocytic (Hürthle cell) 
neoplasm/suspicious for follicular or oncocytic (Hürthle 
cell) neoplasm (FN/SFN), suspicious for malignant cells 
(SMC), or positive for malignant cells (PMC) [11]. Four 
of these diagnoses (AUS/FLUS, FN/SFN, SMC, and 
PMC) were considered as the object of this investiga-
tion, and these patients were invited to participate in 
the study. No additional pre-selection criteria were 
used. Genetic investigation of the BRAF V600E mu-
tation was performed for all of the FNAB cytology 
specimens of these four groups. Surgeons were aware 
of the genetic investigation results, and it did not have 
any influence on the extension of the operation. All 
patients underwent thyroid surgery (lobisthmectomy 
or thyroidectomy, with or without lymph node dissec-
tion). Routine histological examination of the removed 
thyroid tissue was then performed. Additional analysis 
of the BRAF V600E mutation from the histology speci-
men was performed for patients in whom the BRAF 
V600E mutation was not detected in the initial FNAB 
cytology specimen but who were diagnosed with TC 
after the postoperative histological examination. 
Genetic investigation of the BRAF V600E mutation 
Material from the liquid-based preparation or histol-
ogy specimen was transferred into 1.5-ml tubes and 
treated with RBC lysis solution. Genomic DNA was 
extracted with the GeneJET Genomic DNA Purification 
Kit (Thermo Scientific, Vilnius, Lithuania). In order to 
detect the BRAF V600E mutation (GTG > GAG), we 
developed a Real-Time PCR assay comprised of two 
types of reactions. The first one served as an internal 
reference sample control flanking the BRAF codon V600 
of the BRAF gene. The second reaction, or the mutation 
specific reaction, was designed to specifically target 
the GTG > GAG mutation. Primers were predesigned 
manually and investigated in silico using the Oligo-
Calc web tool [12]. A BRAF V600E mutation specific 
forward primer was edited manually by introducing 
a relevant mismatch nucleotide at the 3’ end accord-
ing to the Amplification Refractory Mutation System 
primer design approach [13, 14]. Both reactions shared 
the same reverse primer. Primer sequences were as fol-
lows: BRAF_V600E_ Forward gtgattttggtctagctacggag; 
BRAF_Forward taggtgattttggtctagctacag; BRAF_Re-
verse CATCCACAAAATGGATCCAGAC. Real-Time 
PCR reactions were performed in duplicates using 
a Maxima™ SYBR Green qPCR Master Mix supplement-
ed with 0.4 units per reaction of UNG (both Thermo 
Scientific, Vilnius, Lithuania), 300 nmol of each primer 
Introduction
Thyroid cancer (TC) is the most common endocrine 
malignancy, with an increasing incidence in the Western 
world [1]. Papillary thyroid carcinoma (PTC) accounts 
for 85–90% of all of the thyroid malignancies [2]. Up 
to the present date, ultrasonography (US)-guided 
fine-needle aspiration (FNA) and cytological assess-
ment of the aspirate has been considered a standard 
diagnostic method for the diagnosis of various thy-
roid nodules detected on US [3, 4]. It is a simple, safe, 
and cost-effective diagnostic tool [5]. Although most 
cytology of the aspirates will benefit diagnostically, 
approximately 30% of thyroid aspirates are classified 
as nondiagnostic/unsatisfactory (ND/UNS) or indeter-
minate [6]. Most patients with indeterminate cytology 
still undergo surgery for definitive evaluation; how-
ever, only 8–17% of such surgically removed nodules 
are malignant [1, 7]. Consequently, for patients with 
indeterminate aspirates, surgery is performed for both 
diagnostic and therapeutic purposes. It should, how-
ever, ideally be reserved for therapeutic reasons [8]. Re-
cently, molecular testing of FNAB specimens for genetic 
alterations frequently associated with TC has emerged 
as another valuable diagnostic tool. A point mutation of 
the BRAF V600E oncogene, which results in a change 
from valine to glutamate in codon V600E, has been 
reported in 30–80% of PTC patients [7]. It plays a role 
in cell proliferation, differentiation, and apoptosis [6]. 
Furthermore, some authors state that there is a direct 
association between the BRAF mutation and aggressive 
clinical outcomes such as invasion, metastasis, relapse 
of PTC, or loss of radioiodine avidity in recurrent PTC 
[9]. Identification of the BRAF V600E mutation has high 
specificity and a positive prediction value (PPV) for PTC 
[7]. Nevertheless, it is important to consider that the 
prevalence of the BRAF V600E mutation depends on its 
detection methods, geographical factors, and age [10]. 
The object was to determine the value of reassessing the 
presence of the BRAF V600E mutation in making the 
diagnosis of PTC. The results of the FNAB cytology and 
its genetic analysis were evaluated by means of definite 
histopathological diagnosis and genetic investigation of 
initially BRAF V600E-negative TC histology specimens.
Material and methods
Between January 2012 and January 2015 all patients 
with an US-suspicious thyroid nodule underwent an 
US-guided FNAB in the Vilnius University Hospital 
Santariskiu Clinics. Each of the aspirates was transferred 
to a liquid-based preparation for routine cytological 
assessment. The results of the cytological investiga-
tion were classified based on the Bethesda System for 
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(Metabion, 82152 Planegg/Steinkirchen, Germany), 
and 0.005–0.05 µg of DNA in a 20 µl reaction volume. 
Real-Time PCR reaction conditions on a Bio-Rad CFX96 
system (Bio-Rad Laboratories, Hercules, CA, USA) were 
as follows: 2 minutes at 50°C, 95°C 10 minutes, and 
37 cycles of 95°C 15 seconds 60°C 1 minute. The first 
20 BRAF V600E-positive and 20 — negative cases were 
confirmed by sequencing the histology specimens and 
a sequencing assay published elsewhere [15]. The sen-
sitivity of the Real-Time PCR assay was tested by serial 
dilutions of previously sequenced highly positive BRAF 
V600E DNA in negative DNA. The Real-Time PCR assay 
proved to detect mutant DNA down to a 2.5 log dilution 
in wild-type background.
Statistical analysis
The genetic analysis results of the cytology and histol-
ogy specimens were considered as true positive (TP) 
when the BRAF V600E mutation was detected and the 
patients were diagnosed with PTC in the final histologi-
cal examination. Results were defined as true negative 
(TN) when BRAF V600E mutation was not identified 
and histological investigation revealed benign or other 
non-papillary type of TC. False negative (FN) results 
included cases that were negative for the BRAF V600E 
mutation but were diagnosed with PTC in final histol-
ogy. False positive cases (FP) were defined as positive for 
the BRAF V600E mutation but, after further histological 
investigation, benign or non-papillary type TC was 
confirmed. The following computational formulas were 
used: sensitivity = [TP/(TP + FN)] × 100, specificity = 
= [TN/(TN + FP)] × 100, positive predictive value 
(PPV) = [TP/ (TP + FP)] × 100, negative predictive value 
(NPV) = [TN/ (TN + FN)] × 100. Statistical analysis was 
performed using SPSS software (SPSS Inc., Chicago, 
IL). Continuous variables were analysed by means of 
Student’s t-test. Categorical variables were analysed 
with the use of Pearson Chi-square test. Two-sided P 
values of less than 0.05 were considered to indicate 
statistical significance. 
Results
US-guided FNAB, cytological assessment with genetic 
investigation of the aspirated thyroid material, and 
histological investigation of the surgically removed 
thyroid tissue was performed for a total of 214 patients. 
All of the 214 (100%) patients were Europeans, citizens 
of Lithuania. Thirty (14.02%) of them were male and 
184 (85.98%) were female. The average age of the pa-
tients was 54.76 ± 13.26 years. Sixteen (7.48%) of the 
214 FNABs were classified as AUS/FLUS, 109 (50.93%) as 
FN/SFN, 40 (18.69%) as SMC, and 49 (22.90%) as PMC. 
The BRAF V600E mutation was revealed in 62 (28.97%) 
of the FNABs. After the final histological investigation, 
a total of 106 (49.53%) patients were diagnosed with TC. 
Ninety-five (89.62%) of them were diagnosed with PTC, 
eight (7.55%) with follicular thyroid cancer (FTC), two 
(1.89%) with medullary (MTC), and one (0.94%) with 
anaplastic thyroid cancer (ATC). Forty-four cytologically 
BRAF V600E-negative TC cases underwent further 
genetic investigation of the histological specimen. 
Twelve (27.27%) of them were positive for the BRAF 
V600E mutation. All 74 (100%) BRAF positive cases 
were diagnosed with PTC: 71 (95.95%)- classical type, 
3 (4.05%)- follicular type of PTC (Table I).
Detection of the BRAF V600E mutation  
in papillary thyroid cancer
Out of the 106 patients with histologically confirmed TC, 
the majority (95 (89.62%) cases) were diagnosed with 
PTC. Out of these 95 PTC cases, 88 (92.63%) were classi-
fied as the classical type and 7 (7.37%) as follicular type.
During routine cytological examinations 95 PTC cas-
es were classified as follows: AUS/FLUS — 4 (4.21%), FN/ 
/SFN — 18 (18.95%), SMC — 27 (28.42%), and PMC — 
46 (48.42%). The BRAF V600E mutation was positive in 
62 (65.26%) and negative in 33 (34.74%) FNABs. Detec-
tion of the BRAF V600E mutation in the FNA cytological 
specimen, when confirming PTC, was considered true 
positive in 62 cases, true negative in 119, false positive 
in 0, and false negative in 33 cases. The sensitivity and 
specificity of this mutation detection for making the 
diagnosis of papillary thyroid carcinoma were 65.26% 
and 100%, respectively. Positive predictive value of the 
BRAF V600E mutation was 100%; negative predictive 
value was 78.29%. 
After the additional genetic investigation of the post-
operative histological specimens in cytologically BRAF 
V600E-negative PTC cases, 12 additional BRAF V600E 
positive cases were identified. A total of 74 (77.89%) PTC 
cases were positive for the BRAF V600E mutation and 
21 (22.11%) were negative (Table II). Investigation of 
the histological specimen increased true positive cases 
from 62 to 74 and decreased the amount of false nega-
tive cases from 33 to 21. The sensitivity of this mutation 
detection for making the diagnosis of papillary thyroid 
carcinoma increased from 65.26% to 77.89%. Likewise, 
the negative predictive value increased to 85% from 
78.29% (Table III).
Discussion
Nodular thyroid disease is one of the most frequently 
diagnosed pathologies, which affects up to 50% of the 
adult population in iodine-deficient regions [16]. It is 
less frequent amongst young people and increases 
progressively with age [10]. Frequent use of sensitive 
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diagnostic techniques such as high-resolution ultra-
sonography, computerised tomography, and magnetic 
resonance or positron emission tomography may be 
responsible for incidental detection of thyroid tumours. 
Furthermore, true increases in incidence rates of thyroid 
cancers can also be explained by increased environmen-
tal radiation, use of medical radiation, iodine intake, the 
Chernobyl disaster, carcinogens, and environmental, 
ethnic, and genetic factors or combinations of them [9]. 
Due to its technical simplicity and low cost, US-
guided fine-needle aspiration (FNA) is reported to be 
the first choice diagnostic procedure in the clinical 
management of nodular thyroid disease [5]. FNAB 
has been reported to have high sensitivity (65–99%) 
and specificity (72–100%) in making the diagnosis of 
thyroid malignancies [17]. Even though the criteria for 
Table II. BRAF status detection in different thyroid cancer types(n = 106)
Tabela II. Wykrywanie statusu BRAF w różnych typach raka tarczycy (n = 106)
TC type /BRAF V600E 
status
Cytology specimen Cytology + Histology specimens p value
BRAF V600E positive BRAF V600E negative BRAF V600E positive BRAF V600E negative
Papillary n = 95 62 (65.26%) 33 (34.74%) 74 (77.89%) 21 (22.11%) 0.05
Follicular n = 8 0 (0%) 8 (100%) 0 (0%) 8 (100%) > 0.99
Medullar n = 2 0 (0%) 2 (100%) 0 (0%) 2 (100%) > 0.99
Anaplastic n = 1 0 (0%) 1 (100%) 0 (0%) 1 (100%) > 0.99
Table III. Specifications of BRAF mutation status detection 
in papillary thyroid cancer (n = 214)
Tabela III. Specyfikacje wykrywania statusu mutacji BRAF 
dla raka brodawkowatego tarczycy (n = 214)
Specification/
Specimen type
Cytology  
specimen
Cytology + 
 Histology specimen
TP 62 74
TN 119 119
FN 33 21
FP 0 0
Sensitivity 65.26% 77.89%
Specificity 100% 100%
PPV 100% 100%
NPV 78.29% 85%
Table I. Main data (n = 214)
Tabela I. Dane główne (n = 214)
AUS/FLUS (a)
(n = 16)
FN/SFN (b)
(n = 109)
SMC (c)
 (n = 40)
PMC (d)
(n = 49)
p
value
Mean age (years) 62.50 ± 12.65 53.03 ± 13.45 55.28 ± 12.83 55.67 ± 12.72 0.5
a + b vs. c + d
Gender
Male
Female
3 (18.75%)
13 (81.25%)
18 (16.51%)
91 (83.49%)
6 (15%)
34 (85%)
3 (6.12%)
46 (93.88%)
0.17
a + b vs. c + d
Histology
Benign
Malignant
12 (75%)
4 (25%)
86 (78.90%)
23 (21.10%)
8 (20%)
32 (80%)
2 (4.08%)
47 (95.92%)
< 0.01
a + b vs. c + d
BRAF V600E status
(Cytology specimen)
Positive
Negative
1 (6.25%)
15 (93.75%)
6 (5.50%)
103 (94.50%)
16 (40%)
24 (60%)
39 (79.59%)
10 (20.41%)
<0.01
a + b vs. c + d
BRAF V600E status
(Cytology + Histology specimen)
Positive
Negative
3 (18.75%)
13 (81.25%)
8 (7.34%)
101 (92.66%)
21 (52.50%)
19 (47.50%)
42 (85.71%)
7 (14.29%)
< 0.01
a + b vs. c + d
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the diagnosis of the most common thyroid malignan-
cies have been well described, in a large number of 
samples cytomorphological examination of FNA alone 
does not differentiate well between non-neoplastic and 
neoplastic lesions [18, 19]. The well-differentiated nature 
of most thyroid cancers and their morphologic overlap 
with benign nodules result in the placement of 10% to 
26% of thyroid cytology cases in one of the three indeter-
minate diagnostic categories. Diagnostic thyroidectomy 
is still often required for such patients in order to make 
a definitive evaluation of the suspicious thyroid nodule 
[7, 18, 20]. Ali and Cibas estimated the risk of malignancy 
as follows: 5% to 15% for AUS/FLUS, 15% to 30% for FN/ 
/SFN, and 60 to 75% for SMC [20]. Repeated FNA, core 
biopsy, and even intraoperative frozen sections are often 
unsuccessful at clarifying the nature of these ambiguous 
nodules [6]. However, it has been observed that during 
the histopathological evaluation of the excised thyroid 
piece more than two thirds of initially indeterminate 
significance lesions are, in fact, benign [5]. Our study 
reflects literature findings; 64.24% of the operated 
cases with an indeterminate cytological diagnosis were 
histologically found to be benign. For these patients, 
thyroid surgery is unnecessary; undergoing such sur-
gery exposes them to a 2–10% risk of serious surgical 
complications, and for most a lifetime of levothyroxine 
replacement therapy [8]. Moreover, patients with malig-
nant tumours and indeterminate FNA cytology typically 
undergo a limited surgery, i.e. thyroid lobectomy. After 
the diagnosis of the malignancy has been established 
by pathological examination of the removed nodule, 
these patients require a second operation to complete 
the thyroidectomy, which is associated with additional 
costs and increased rate of morbidity [21]. 
Out of all thyroid cancer types PTC is the most fre-
quent, accounting for approximately 85–90% of all TC, 
whereas FTC accounts for about 10% or less, and ATC 
is very rare (approximately 1–2%) [22]. We have found 
similar frequency rates of TC types: PTC — 89.62%, 
FTC — 7.55%, MTC — 1,89%, and ATC — 0.94%. PTC 
is characterised by slow growth and long existence, thus 
patients generally have good 5- and 10-year survival 
rates [23, 24]. The favourable survival is partly due to 
PTC being a normal finding; rather than being called 
carcinoma, some authors say it should be called a be-
nign papillary tumour [25]. However, 20 to 30% of these 
patients develop local recurrence or distant metastasis, 
and 1% of the cases are lethal [26]. 
Recently, knowledge of molecular genetics of thy-
roid cancer has started to be transferred into clinical 
practice. The main goal of recent studies is to improve 
the accuracy of FNA biopsy assessment and to predict 
tumour behaviour. A number of genetic mutations are 
known to occur in thyroid cancer. PTC may carry point 
mutations of the BRAF V600E and RAS genes, RET/pTC, 
and TRK rearrangements [1]. The BRAF V600E mutation 
is a thymine-to-adenine transversion at nucleotide 1799 
(T1799A), leading to the substitution of valine to glutamic 
acid at residue 600 of the protein (V600E), triggered by 
the binding of RAS and resulting in the tumorogenetic 
activation of the cascade of MEK and ERK of the MAPK 
pathway via phosphorylation [1, 3]. It is the most com-
monly known genetic alteration, found in 30–80% of 
papillary thyroid carcinomas [27]. However, there are 
some demographic differences — with regions in East 
Asia (in particular Korea) reporting a higher incidence 
of approximately 90% [20, 28, 29]. We have found that 
77.89% of PTC cases were positive for the BRAF V600E 
mutation. It is reported that preoperative testing for the 
BRAF V600E mutation may increase the accuracy of the 
diagnosis of PTC in up to 30% of thyroid FNABs that 
were initially diagnosed as indeterminate or suspicious 
for malignancy [18]. The mutation is highly prevalent 
in the tall cell variant of PTC, where it occurs in 70–80% 
of cases, and in tumours with classic papillary growth 
(60%). In contrast, BRAF V600E is found only in about 
10% of follicular variants of PTC [25]. Additionally, 
the BRAF V600E mutation occurs most commonly in 
aggressive subtypes of PTC [9]. In a histopathological 
examination, the presence of the BRAF V600E muta-
tion is associated with higher clinical stage, aggressive 
biological behaviour, such as extra thyroidal extension, 
angiolymphatic invasion, metastases to the lymph nodes, 
and loss of responsiveness to radioiodine [30]. Most im-
portantly, PTC patients who were positive for the BRAF 
V600E mutation had a worse outcome (persistent disease 
and lower survival rate) during a 15-year follow-up [31]. 
Finally, because targeted therapy for thyroid cancers 
with multikinase inhibitors is under rapid development, 
the detection of mutations in the FNA material may be 
helpful in the future to guide mutation-specific targeted 
therapies that can be initiated preoperatively or for those 
patients who are not surgical candidates [21]. 
To sum up, PTC accounts for the majority of all thy-
roid malignancies and has a relatively benign nature. 
The BRAF V600E mutation is reported to have high 
specificity for PTC. Furthermore, comparison of the 
genetic investigations in cytology and histology speci-
mens showed that the BRAF V600E status follow-up can 
help reveal initially BRAF V600E negative PTC cases. 
Conclusions
Repeated examination of the BRAF V600E mutation 
status in the FNA may potentially increase the sensitiv-
ity of diagnosing papillary thyroid cancer. Even though 
the results are encouraging, larger scale prospective 
trials are needed.
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